Piper Sandler Reiterates Overweight on Definium Therapeutics, Raises Price Target to $75

Benzinga Newsdesk www.benzinga.com Positive 71.1%

Neg 0% Neu 0% Pos 71.1%

Piper Sandler analyst David Amsellem reiterates Definium Therapeutics (NASDAQ:DFTX) with a Overweight and raises the price target from $73 to $75.